Capricor Therapeutics, Inc.

DB:4LN2 Stock Report

Market Cap: €630.9m

Capricor Therapeutics Past Earnings Performance

Past criteria checks 0/6

Capricor Therapeutics's earnings have been declining at an average annual rate of -24.2%, while the Biotechs industry saw earnings growing at 7.3% annually. Revenues have been growing at an average rate of 76.3% per year.

Key information

-24.2%

Earnings growth rate

13.2%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate76.3%
Return on equity-50.0%
Net Margin-146.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Capricor Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:4LN2 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2423-34140
30 Jun 2427-28140
31 Mar 2427-24130
31 Dec 2325-22130
30 Sep 2314-29120
30 Jun 239-29120
31 Mar 236-29110
31 Dec 223-29100
30 Sep 222-27100
30 Jun 220-2590
31 Mar 220-2380
31 Dec 210-2080
30 Sep 210-1870
30 Jun 210-1860
31 Mar 210-1760
31 Dec 200-1460
30 Sep 200-1150
30 Jun 201-950
31 Mar 201-740
31 Dec 191-840
30 Sep 191-940
30 Jun 192-1240
31 Mar 192-1450
31 Dec 182-1550
30 Sep 181050
30 Jun 182250
31 Mar 182250
31 Dec 173250
30 Sep 173-1450
30 Jun 174-1750
31 Mar 174-1850
31 Dec 164-1950
30 Sep 164-1850
30 Jun 165-1550
31 Mar 165-1440
31 Dec 156-1340
30 Sep 156-1140
30 Jun 156-1040
31 Mar 156-840
31 Dec 145-630
30 Sep 143-930
30 Jun 142-930
31 Mar 141-930

Quality Earnings: 4LN2 is currently unprofitable.

Growing Profit Margin: 4LN2 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4LN2 is unprofitable, and losses have increased over the past 5 years at a rate of 24.2% per year.

Accelerating Growth: Unable to compare 4LN2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4LN2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 4LN2 has a negative Return on Equity (-49.97%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 17:25
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Capricor Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Reni BenjaminH.C. Wainwright & Co.
Joseph PantginisH.C. Wainwright & Co.